MCID: ALL009
MIFTS: 53

Allergic Conjunctivitis

Categories: Immune diseases, Eye diseases

Aliases & Classifications for Allergic Conjunctivitis

MalaCards integrated aliases for Allergic Conjunctivitis:

Name: Allergic Conjunctivitis 12 14 69
Conjunctivitis, Allergic 41
Conjunctivitis Allergic 51

Classifications:



External Ids:

Disease Ontology 12 DOID:11204
MeSH 41 D003233
NCIt 46 C34506
UMLS 69 C0009766

Summaries for Allergic Conjunctivitis

Disease Ontology : 12 A chronic conjunctivitis that is an inflammation of the conjunctiva involing red, itchy, and watery eyes a resulting from an exposure to an allergen or an irritant.

MalaCards based summary : Allergic Conjunctivitis, also known as conjunctivitis, allergic, is related to giant papillary conjunctivitis and pollen allergy. An important gene associated with Allergic Conjunctivitis is RNASE3 (Ribonuclease A Family Member 3), and among its related pathways/superpathways are Innate Immune System and TGF-Beta Pathway. The drugs Alcaftadine and Ephedrine have been mentioned in the context of this disorder. Affiliated tissues include eye, testes and t cells, and related phenotypes are hematopoietic system and homeostasis/metabolism

Wikipedia : 72 Allergic conjunctivitis is inflammation of the conjunctiva (the membrane covering the white part of the... more...

Related Diseases for Allergic Conjunctivitis

Diseases related to Allergic Conjunctivitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 200)
# Related Disease Score Top Affiliating Genes
1 giant papillary conjunctivitis 31.6 CCL11 CXCL8 IL4
2 pollen allergy 31.4 ICAM1 IL13 IL5 RNASE3
3 scleritis 30.2 IL4 IL5
4 uveitis 29.8 ICAM1 IFNG IL4
5 allergic rhinitis 29.6 CCL11 CXCL8 HRH1 ICAM1 IFNG IL13
6 vernal keratoconjunctivitis 29.5 CCL11 ICAM1 IL13 IL4 IL5 RNASE3
7 atopic keratoconjunctivitis 29.5 IFNG IL4 IL5 RNASE3
8 ige responsiveness, atopic 29.4 IFNG IL13 IL4 IL5 RNASE3
9 dermatitis 29.2 CCL11 IFNG IL13 IL4 IL5 RNASE3
10 allergic hypersensitivity disease 28.9 CCL11 HRH1 IFNG IL13 IL4 IL5
11 conjunctivitis 28.8 CCL11 CXCL8 HRH1 ICAM1 IFNG IL13
12 rhinitis 28.4 CCL11 CXCL8 HRH1 ICAM1 IL13 IL4
13 keratoconjunctivitis 28.3 CCL11 CXCL8 ICAM1 IFNG IL13 IL4
14 asthma 26.6 CCL11 CXCL8 HRH1 ICAM1 IFNG IL13
15 dermatitis, atopic 26.3 CCL11 CXCL8 HRH1 ICAM1 IFNG IL13
16 loeffler endocarditis 10.5 IL5 RNASE3
17 cytokine deficiency 10.5 IL13 IL5
18 angioimmunoblastic lymphadenopathy with dysproteinemia 10.5 IL13 IL5
19 beta-lactam allergy 10.4 IL13 IL4
20 cow milk allergy 10.4 IL5 RNASE3
21 pemphigoid gestationis 10.4 CCL11 IL5
22 egg allergy 10.4 IL4 IL5
23 respiratory syncytial virus infectious disease 10.4 IL13 IL5
24 trichinosis 10.4 IL4 IL5
25 non-suppurative otitis media 10.4 IL4 IL5
26 chronic meningitis 10.4 CCL11 IL5
27 blepharitis 10.4 CCL11 IL4
28 nut allergy 10.4 IL13 IL5
29 diversion colitis 10.4 ICAM1 IL4
30 cercarial dermatitis 10.4 IL4 IL5
31 mycoplasmal pneumonia 10.4 IFNG IL4
32 hyperlucent lung 10.3 IFNG IL4
33 blepharoconjunctivitis 10.3 CCL11 IL4 RNASE3
34 night blindness, congenital stationary, type 1a 10.3 IL13 IL5
35 b-cell growth factor 10.3 IFNG IL4
36 cough variant asthma 10.3 IL4 IL5 RNASE3
37 radiation cystitis 10.3 IL13 IL5
38 intrinsic asthma 10.3 IL4 IL5 RNASE3
39 baylisascariasis 10.3 IFNG IL4
40 african tick-bite fever 10.3 IFNG IL13
41 eosinophilic fasciitis 10.3 IFNG IL5
42 paragonimiasis 10.3 IL13 IL5 RNASE3
43 milk allergy 10.3 IL4 IL5 RNASE3
44 actinic prurigo 10.3 ICAM1 IL13
45 apple allergy 10.3 IL13 IL4 IL5
46 intestinal schistosomiasis 10.3 IL13 IL4 IL5
47 chronic tic disorder 10.3 IL13 IL4 IL5
48 eosinophilic gastroenteritis 10.3 CCL11 IL5 RNASE3
49 enterobiasis 10.3 IL13 IL4 IL5
50 primary amebic meningoencephalitis 10.3 IL4 IL5

Graphical network of the top 20 diseases related to Allergic Conjunctivitis:



Diseases related to Allergic Conjunctivitis

Symptoms & Phenotypes for Allergic Conjunctivitis

MGI Mouse Phenotypes related to Allergic Conjunctivitis:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.96 IL33 IL4 CCL11 IL5 HRH1 ICAM1
2 homeostasis/metabolism MP:0005376 9.81 IL13 IL33 IL4 HRH1 IL5 PTGDR2
3 digestive/alimentary MP:0005381 9.8 IL13 IL33 IL4 IL5 ICAM1 IFNG
4 immune system MP:0005387 9.65 IL33 IL4 CCL11 IL5 HRH1 ICAM1
5 respiratory system MP:0005388 9.17 IL13 IL33 IL4 CCL11 IL5 TLR3

Drugs & Therapeutics for Allergic Conjunctivitis

Drugs for Allergic Conjunctivitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 116)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Alcaftadine Approved Phase 4,Phase 3 147084-10-4 19371515
2
Ephedrine Approved Phase 4,Phase 3,Phase 2,Phase 1 299-42-3 9294
3
Histamine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 51-45-6, 75614-87-8 774
4
Naphazoline Approved Phase 4,Phase 3 835-31-4 4436
5
Pheniramine Approved Phase 4 86-21-5 4761
6
Pseudoephedrine Approved Phase 4,Phase 3,Phase 2,Phase 1 90-82-4 7028
7
Tacrolimus Approved, Investigational Phase 4,Phase 2 104987-11-3 445643 439492
8
Epinastine Approved, Investigational Phase 4,Phase 3 80012-43-7 3241
9
Loteprednol Approved Phase 4,Phase 3,Phase 2 129260-79-3, 82034-46-6 9865442 444025
10
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 50-02-2 5743
11
Ketotifen Approved Phase 4,Phase 3,Phase 2,Phase 1 34580-13-7, 34580-14-8 3827
12
Methylprednisolone Approved, Vet_approved Phase 4,Phase 2 83-43-2 6741
13
Prednisolone Approved, Vet_approved Phase 4,Phase 2 50-24-8 5755
14
Dipivefrin Approved Phase 4 52365-63-6 3105
15
Tranilast Approved, Investigational Phase 4 53902-12-8 93543
16
Desloratadine Approved, Investigational Phase 4 100643-71-8 124087
17
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 22916-47-8 4189
18
Montelukast Approved Phase 4 158966-92-8 5281040
19
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741 24759
20
Pimecrolimus Approved, Investigational Phase 4 137071-32-0 17753757 6447131
21
Maleic acid Experimental Phase 4 110-16-7 444266
22 Ophthalmic Solutions Phase 4,Phase 3,Phase 2,Phase 1
23 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1
24 Adrenergic Agents Phase 4,Phase 3,Phase 2
25 Adrenergic Agonists Phase 4,Phase 3,Phase 2
26 Adrenergic alpha-Agonists Phase 4,Phase 3,Phase 2
27 Anti-Allergic Agents Phase 4,Phase 3,Phase 2,Phase 1
28 Antipruritics Phase 4,Phase 3,Phase 2,Phase 1
29 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1
30 Histamine Antagonists Phase 4,Phase 3,Phase 2,Phase 1
31 Histamine H1 Antagonists Phase 4,Phase 3,Phase 2,Phase 1
32
Histamine Phosphate Phase 4,Phase 3,Phase 2,Phase 1 51-74-1 65513
33 Nasal Decongestants Phase 4,Phase 3,Phase 2,Phase 1
34 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1
35 Respiratory System Agents Phase 4,Phase 3,Phase 2,Phase 1
36 Vasoconstrictor Agents Phase 4,Phase 3,Phase 2,Phase 1
37 Tetrahydrozoline Phase 4,Phase 3,Phase 2,Phase 1
38 Analgesics Phase 4,Phase 3,Phase 2,Phase 1
39 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2,Phase 1
40 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1
41 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 3,Phase 2,Phase 1
42 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1
43 Histamine H1 Antagonists, Non-Sedating Phase 4,Phase 3,Phase 2,Phase 1
44 Olopatadine Hydrochloride Phase 4,Phase 3,Phase 2,Phase 1
45 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
46 Calcineurin Inhibitors Phase 4,Phase 3,Phase 2
47 Immunosuppressive Agents Phase 4,Phase 3,Phase 2
48 Antiemetics Phase 4,Phase 3,Phase 2
49 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2
50 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 132)

# Name Status NCT ID Phase Drugs
1 Use of BEPREVE (Bepotastine Besilate Ophthalmic Solution) 1.5% for Allergic Conjunctivitis and Contact Lenses Unknown status NCT01337557 Phase 4 Bepotastine
2 Comparison of Tolerability Between Two Allergy Drops Unknown status NCT01390961 Phase 4 alacaftadine and naphazoline HCl & pheniramine maleate
3 The Effect of BEPREVE 1.5% on Tear Film Osmolarity and Tear Film Lipid Layer Unknown status NCT01346371 Phase 4 Bepreve (bepotastine ophthalmic solution) 1.5%
4 Ocular Allergy Treatment Practical Impact Trial Unknown status NCT01808768 Phase 4 Alcaftadine
5 Confocal Analysis of Corneal Structures of Symptomatic Allergic Conjunctivitis Patients Completed NCT01697969 Phase 4 Olopatadine hydrochloride ophthalmic solution, 0.2%
6 Effectiveness of Olopatadine HCl Ophthalmic Solution for the Treatment of Allergic Conjunctivitis in Japan Completed NCT02251613 Phase 4 Olopatadine HCl ophthalmic solution, 0.1%;Epinastine HCl ophthalmic solution, 0.05%
7 Bepreve vs. Alrex in Subjects With Moderate to Severe Allergic Conjunctivitis Completed NCT01443442 Phase 4 bepotastine besilate, 1.5%;Loteprednol etabonate
8 A Study of Patient Perception and Quality of Life Associated With the Use of Olopatadine 0.2% in Subjects With Allergic Conjunctivitis Completed NCT01272089 Phase 4 Olopatadine Hydrochloride Ophthalmic Solution, 0.2%
9 Assessing the Efficacy of Maxidex® and Patanol® for the Treatment of Allergic Conjunctivitis Completed NCT01119287 Phase 4 Dexamethasone 0.1% ophthalmic suspension;Olopatadine hydrochloride 0.1% ophthalmic solution
10 Evaluation of the Effect and Tolerance of Preservative Free NAAGA on the Inflammatory Component and Symptoms of Dry Eye Syndrome in Allergic Conjunctivitis Patients Completed NCT01203540 Phase 4 NAABAK eyedrops;Saline eyedrops
11 Ketotifen Ophthalmic Solution With Emedastine in Patients With Seasonal Allergic Conjunctivitis Completed NCT00133627 Phase 4 Ketotifen
12 Patient Perceptions and Quality of Life Associated With the Use of Olapatadine 0.2% for the Treatment of Allergic Conjunctivitis Completed NCT01159769 Phase 4 Olopatadine hydrochloride ophthalmic solution, 0.2% (Pataday®)
13 A Comparison of Olopatadine and Fluticasone in Patients With Allergic Conjunctivitis Completed NCT00655109 Phase 4 Olopatadine;Fluticasone;Saline;Artificial tears
14 Non-Pharmaceutical Treatment of Seasonal Allergic Conjunctivitis Completed NCT01569191 Phase 4 Anti-allergic Medication
15 Study of Two Marketed Ocular Anti-Allergy Medications in Subjects With Allergic Conjunctivitis Completed NCT00534794 Phase 4 Elestat;Pataday
16 Patient Perception Study for AL-4943A Completed NCT01294969 Phase 4 AL-4943A
17 Clinical Evaluation of 0.1% Olopatadine Hydrochloride Ophthalmic Solution in Pediatric Patients Completed NCT01109485 Phase 4 Olopatadine hydrochloride ophthalmic solution 0.1%
18 Evaluation of the Efficacy of Topical Ophthalmic Steroids in a Modified Conjunctival Allergen Challenge Model Completed NCT00689078 Phase 4 Prednisolone Acetate 1%;Prednisolone Acetate 0.12%;Loteprednol Etabonate 0.2%;Artificial tears
19 Evaluation of the Efficacy of Topical Ophthalmic Steroids in a Modified Conjunctival Allergen Challenge (CAC) Model Completed NCT01534195 Phase 4 Prednisolone Sodium Phosphate Ophthalmic Solution 1%;Tears Naturale II Ophthalmic Solution
20 Assessment of Alcon's Ocular Image Quantification System Completed NCT01282138 Phase 4 Olopatadine hydrochloride, 0.1% ophthalmic solution (Patanol)
21 Mast-Cell Stabilizing Effects of Olopatadine Completed NCT00389025 Phase 4 Olopatadine (generic name)
22 Efficacy Investigation Study of Olopatadine Hydrochloride Ophthalmic Solution Using OHIO Chamber in Patients With Seasonal Allergic Rhinitis (SAR) Completed NCT00818805 Phase 4 Olopatadine 0.1%;Tranilast 0.5%;Placebo (Olopatadine);Placebo (Tranilast)
23 A Study to Evaluate the Duration of LASTACAFT® in Acute Allergic Conjunctivitis Completed NCT01470118 Phase 4 alcaftadine 0.25% ophthalmic solution;olopatadine 0.2% ophthalmic solution;dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%
24 A Study to Evaluate the Efficacy of Lastacaft® Compared to Pataday™ and Placebo in Patients With Acute Allergic Conjunctivitis Completed NCT01732757 Phase 4 Alcaftadine 0.25%;Olopatadine 0.2%;dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%
25 Study of the Effect of Fluticasone Furoate Nasal Spray on Spring Allergy Eye Symptoms Completed NCT00891436 Phase 4 Fluticasone furoate nasal spray;Placebo nasal spray
26 A Single-Center Evaluation of the Anti-Inflammatory Effects of Lastacaft as Measured by In-Vivo Confocal Microscopy Completed NCT02308501 Phase 4 Lastacaft ®;Tears Naturale ®
27 Evaluation of Prednisolone in a Modified Conjunctival Allergen Challenge Model Completed NCT01730872 Phase 4 Prednisolone Sodium Phosphate Ophthalmic Solution 1%;Tears Naturale II Ophthalmic Solution
28 An Allergen BioCube (ABC) Study Evaluating the Efficacy of Fluticasone Propionate Nasal Spray Compared to Placebo Completed NCT01439815 Phase 4 Fluticasone Propionate Nasal Spray;Saline Nasal Spray
29 The Evaluation of Bepreve on the Measurement of Wheal and Flare Response From Histamine Skin Prick Testing Completed NCT01128556 Phase 4 Bepreve;Refresh Tears
30 A Study of the Effects of Desloratadine on Conjunctival Allergen Challenge-induced Ocular Signs and Symptoms (Study P04209) Completed NCT00311844 Phase 4 desloratadine
31 Topical Cyclosporine for Vernal Keratoconjunctivitis (VKC) in Rwanda Completed NCT01211327 Phase 4 Cyclosporine A;Dexamethasone
32 Montelukast as a Controller of Atopic Syndrome Completed NCT00559546 Phase 4 montelukast
33 Clinical Evaluation of Hylo-Dual Versus Patanol in Children With Seasonal Allergic Conjunctivitis Recruiting NCT03186755 Phase 4 Hyaluronic acid 0.05% & Ectoine 2.0%;Olopatadine hydrochloride ophthalmic solution 0.1%
34 A Study to Evaluate the Safety and Efficacy of Lotemax Ophthalmic Suspension 0.5% Active, not recruiting NCT01437982 Phase 4 Loteprednol Etabonate;Prednisolone Acetate 1% Oph Susp
35 Alleviation of Cedar Pollen Induced Allergic Symptoms by Orally Taken Superfine Beta-1,3-Glucan Terminated NCT00276445 Phase 4 beta-1,3-glucan
36 Safety and Efficacy of Pimecrolimus Cream 1% in Atopic Disease Modification Terminated NCT00124709 Phase 4 Pimecrolimus;Corticosteroid
37 Comparison of CL Wear Between Two Allergy Drops Withdrawn NCT00489398 Phase 4 epinastine HCL and olopatadine HCL
38 A Multicenter Study to Evaluate Safety and Efficacy of Specific Immunotherapy With Modified Allergen Extracts Unknown status NCT01012752 Phase 3
39 Use of Probiotic Bacteria in Prevention of Allergic Disease in Children 1999-2008 Unknown status NCT00298337 Phase 2, Phase 3 Mixture of probiotic bacteria and prebiotic oligosaccharide
40 Efficacy and Safety of AL-4943A Ophthalmic Solution in Patients With Allergic Conjunctivitis Using the Conjunctival Allergen Challenge (CAC) Model Completed NCT01479374 Phase 3 AL-4943A ophthalmic solution;AL-4943A vehicle;Olopatadine hydrochloride ophthalmic solution, 0.2%
41 Evaluation of Efficacy and Safety of an Anti-Allergy Drug With a Contact Lens in Allergic Conjunctivitis Completed NCT00432757 Phase 3 Ketotifen with a Contact Lens (generic name not yet established)
42 Evaluation of Efficacy and Safety of an Anti-Allergy Drug With a Contact Lens in the Treatment of Allergic Conjunctivitis Completed NCT00445874 Phase 3 Ketotifen with a Contact Lens (no generic name)
43 Evaluation of Efficacy of Ophthalmic Solution in Seasonal Allergic Conjunctivitis Completed NCT00364091 Phase 3 R89674 0.025% ophthalmic solution
44 Evaluation of Efficacy of Ophthalmic Solution in Induced Allergic Conjunctivitis Completed NCT00244543 Phase 3 R89674 (generic name not yet established)
45 Evaluation of Efficacy of Ophthalmic Solution in Induced Acute Allergic Conjunctivitis Completed NCT00241319 Phase 3 R89674 (generic name not yet established)
46 Efficacy and Safety of an Ophthalmic Solution in Patients With Allergic Conjunctivitis Completed NCT01743027 Phase 3 AL-4943A ophthalmic solution;Olopatadine hydrochloride ophthalmic solution, 0.2%;Olopatadine hydrochloride ophthalmic solution, 0.1%;AL-4943A ophthalmic solution vehicle
47 Study Evaluating Efficacy and Safety of OTX-DP for Treatment of Chronic Allergic Conjunctivitis Completed NCT02445326 Phase 3 OTX-DP treatment
48 Study Evaluating the Efficacy and Safety of OTX-DP for the Treatment of Chronic Allergic Conjunctivitis Using a Modified Conjunctival Allergen Challenge Model (CAC®) Completed NCT02988882 Phase 3 OTX-DP (Dexamethasone)
49 A Long-term Study of DE-114 Ophthalmic Solution in Patients With Allergic Conjunctivitis Completed NCT01363713 Phase 3 DE-114 ophthalmic solution
50 Study of DE-114 Ophthalmic Solution in Patients With Allergic Conjunctivitis Completed NCT01363700 Phase 3 DE-114 ophthalmic solution;Placebo ophthalmic solution;Olopatadine Hydrochloride 0.1% Ophthalmic Solution

Search NIH Clinical Center for Allergic Conjunctivitis

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cochrane evidence based reviews: conjunctivitis, allergic

Genetic Tests for Allergic Conjunctivitis

Anatomical Context for Allergic Conjunctivitis

MalaCards organs/tissues related to Allergic Conjunctivitis:

38
Eye, Testes, T Cells, Skin, Endothelial, B Cells, Monocytes

Publications for Allergic Conjunctivitis

Articles related to Allergic Conjunctivitis:

(show top 50) (show all 597)
# Title Authors Year
1
Allergic Conjunctivitis-induced Retinal Inflammation Promotes Myopia Progression. ( 29398596 )
2018
2
Rapamycin attenuates Th2-driven experimental allergic conjunctivitis. ( 29432811 )
2018
3
Tear osteopontin level and its relationship with local Th1/Th2/Th17/Treg cytokines in children with allergic conjunctivitis. ( 29279263 )
2018
4
A Biodegradable, Sustained-Released, Tacrolimus Microfilm Drug Delivery System for the Management of Allergic Conjunctivitis in a Mouse Model. ( 29392313 )
2018
5
Allergic Conjunctivitis in Patients with Respiratory Allergic Symptoms; a Retrospective Study in Greece. ( 28428968 )
2017
6
Increased red cell distribution width levels in children with seasonal allergic conjunctivitis. ( 28523524 )
2017
7
Efficacy of 0.05% epinastine and 0.1% olopatadine for allergic conjunctivitis as seasonal and preseasonal treatment. ( 29026285 )
2017
8
Effect of Mandarin Orange Yogurt on Allergic Conjunctivitis Induced by Conjunctival Allergen Challenge. ( 28593244 )
2017
9
Risk of allergic conjunctivitis in patients with type 1 diabetes mellitus: a population-based retrospective cohort study. ( 28630085 )
2017
10
Diagnosis and management of allergic conjunctivitis in pediatric patients. ( 28052798 )
2017
11
An inhibitor peptide of toll-like receptor 2 shows therapeutic potential for allergic conjunctivitis. ( 28246054 )
2017
12
Clinical implications of mast cell involvement in allergic conjunctivitis. ( 29105783 )
2017
13
Correction: Effects of Exposure to Ozone on the Ocular Surface in an Experimental Model of Allergic Conjunctivitis. ( 28245290 )
2017
14
Pooled analysis of two studies evaluating efficacy and safety of olopatadine hydrochloride 0.77% in patients with allergic conjunctivitis. ( 28652694 )
2017
15
Efficacy of oral immunotherapy with a rice-based edible vaccine containing hypoallergenic Japanese cedar pollen allergens for treatment of established allergic conjunctivitis in mice. ( 28676431 )
2017
16
Superoxide dismutase 3 attenuates experimental Th2-driven allergic conjunctivitis. ( 28063939 )
2017
17
Redness response phenotypes of allergic conjunctivitis in an allergen challenge chamber. ( 28007090 )
2017
18
Evaluation of allergic sensitization in Lebanese patients with allergic conjunctivitis. ( 28831678 )
2017
19
Effects of Exposure to Ozone on the Ocular Surface in an Experimental Model of Allergic Conjunctivitis. ( 28046113 )
2017
20
Model for Studying Anti- Allergic Drugs for Allergic Conjunctivitis in Animals. ( 28848937 )
2017
21
Allergic conjunctivitis in Asia. ( 28487836 )
2017
22
Role of CCL7 in Type I Hypersensitivity Reactions in Murine Experimental Allergic Conjunctivitis. ( 27956527 )
2017
23
Nitrite, neopterin levels and tryptophan degradation in allergic conjunctivitis. ( 28779270 )
2017
24
Olopatadine hydrochloride ophthalmic solution for the treatment of allergic conjunctivitis. ( 28656804 )
2017
25
Topical ocular treatment with monoclonal antibody Fab fragments targeting Japanese cedar pollen Cry j 1 inhibits Japanese cedar pollen-induced allergic conjunctivitis in mice. ( 28119075 )
2017
26
Novel oleyl amine-modified polymannuronic acid micelle loading tacrolimus for therapy of allergic conjunctivitis. ( 28655660 )
2017
27
MiR-146a overexpression effectively improves experimental allergic conjunctivitis through regulating CD4(+)CD25(-)T cells. ( 28810531 )
2017
28
Self-Reported Allergic Rhinitis and/or Allergic Conjunctivitis Associate with IL13 rs20541 Polymorphism in Finnish Adult Asthma Patients. ( 28273659 )
2017
29
Efficacy of olopatadine hydrochloride 0.1%, emedastine difumarate 0.05%, and loteprednol etabonate 0.5% for Chinese children with seasonal allergic conjunctivitis: a randomized vehicle-controlled study. ( 27869354 )
2016
30
Risk of Allergic Rhinitis, Allergic Conjunctivitis, and Eczema in Children Born to Mothers with Gum Inflammation during Pregnancy. ( 27224053 )
2016
31
TRPV1 Antagonist Suppresses Allergic Conjunctivitis in a Murine Model. ( 27726468 )
2016
32
Evaluating the efficacy of epinastine ophthalmic solution using a conjunctivitis allergen challenge model in patients with birch pollen allergic conjunctivitis. ( 27720602 )
2016
33
Expression of TSLP and Downstream Molecules IL-4, IL-5, and IL-13 on the Eye Surface of Patients with Various Types of Allergic Conjunctivitis. ( 27504196 )
2016
34
Treatment with olopatadine and naphazoline hydrochloride reduces allergic conjunctivitis in mice through alterations in inflammation, NGF and VEGF. ( 26936233 )
2016
35
Biomimetic contact lenses eluting olopatadine for allergic conjunctivitis. ( 27221794 )
2016
36
Treating allergic conjunctivitis: A once-daily medication that provides 24-hour symptom relief. ( 27466061 )
2016
37
Development of Allergic Conjunctivitis Induced by House Dust Mite Extract From Dermatophagoides pteronyssinus. ( 27074380 )
2016
38
Ambient air pollution, weather changes, and outpatient visits for allergic conjunctivitis: A retrospective registry study. ( 27033635 )
2016
39
Ocular itch associated with allergic conjunctivitis: latest evidence and clinical management. ( 26770669 )
2016
40
Allergic Conjunctivitis and the Associated Risk of Migraine Among Children: A Nationwide Population-based Cohort Study. ( 27382919 )
2016
41
Topical Application of Interleukin-28A Attenuates Allergic Conjunctivitis in an Ovalbumin-Induced Mouse Model. ( 26886894 )
2016
42
Efficacy and safety of an eye wash solution in allergic conjunctivitis after conjunctival allergen challenge. ( 27788889 )
2016
43
Topical Administration of I^-1,3-Glucan to Modulate Allergic Conjunctivitis in a Murine Model. ( 27002295 )
2016
44
High incidence of dry eye in young children with allergic conjunctivitis in Southwest China. ( 27226346 )
2016
45
Ocular Pharmacology of Tear Film, Dry Eye, and Allergic Conjunctivitis. ( 27913889 )
2016
46
Topical Olopatadine in the Treatment of Allergic Conjunctivitis: A Systematic Review and Meta-analysis. ( 27192186 )
2016
47
Topical Antihistamines and Mast Cell Stabilizers for Treating Allergic Conjunctivitis. ( 27281835 )
2016
48
What is the most effective topical treatment for allergic conjunctivitis? ( 26009742 )
2015
49
Allergic conjunctivitis: a cross-sectional study. ( 25809830 )
2015
50
Epidemiology of allergic conjunctivitis: clinical appearance and treatment patterns in a population-based study. ( 26258920 )
2015

Variations for Allergic Conjunctivitis

Expression for Allergic Conjunctivitis

Search GEO for disease gene expression data for Allergic Conjunctivitis.

Pathways for Allergic Conjunctivitis

Pathways related to Allergic Conjunctivitis according to GeneCards Suite gene sharing:

(show all 40)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.89 CCL11 CXCL8 ICAM1 IFNG IL13 IL33
2
Show member pathways
13.43 CCL11 CXCL8 ICAM1 IFNG IL13 IL4
3
Show member pathways
13.29 CCL11 CXCL8 IL13 IL4 IL5 TLR3
4
Show member pathways
13.27 CCL11 CXCL8 ICAM1 IFNG IL13 IL33
5 12.75 CXCL8 IFNG IL13 IL4 IL5
6
Show member pathways
12.69 CXCL8 ICAM1 IFNG IL13 IL33 IL4
7
Show member pathways
12.66 CCL11 CXCL8 ICAM1 IFNG IL13 IL4
8
Show member pathways
12.5 IFNG IL13 IL4 IL5
9
Show member pathways
12.3 IFNG IL13 IL4 IL5
10
Show member pathways
12.21 CCL11 CXCL8 IFNG IL13 IL4 IL5
11
Show member pathways
12.15 CXCL8 IFNG TLR3
12
Show member pathways
12.12 CCL11 CXCL8 IFNG IL4
13
Show member pathways
12.12 CXCL8 IFNG IL13 IL4 IL5
14
Show member pathways
12.1 IFNG IL33 TLR3
15 11.96 CXCL8 ICAM1 IFNG IL4
16 11.95 CCL11 CXCL8 ICAM1 IL13 IL4
17
Show member pathways
11.94 IL13 IL5 TLR3
18 11.94 IFNG IL4 IL5 PTGDR2
19
Show member pathways
11.79 IFNG IL4 TLR3
20 11.79 CXCL8 ICAM1 IFNG
21
Show member pathways
11.75 CXCL8 IFNG IL4 IL5
22 11.64 ICAM1 IL4 IL5
23 11.61 CCL11 IL4 IL5
24
Show member pathways
11.61 CXCL8 ICAM1 IFNG
25 11.57 CCL11 CXCL8 IL13 IL4 IL5
26 11.55 CXCL8 ICAM1 IFNG IL13 IL4 IL5
27 11.52 CXCL8 ICAM1 IL13 IL4
28 11.49 CXCL8 ICAM1 IFNG
29 11.43 CXCL8 ICAM1 IFNG
30 11.34 IFNG IL13 IL33 IL4 IL5 PTGDR2
31 11.29 IFNG IL4 IL5
32 11.26 IFNG IL13 IL4 IL5
33 11.16 CCL11 CXCL8 IL13 IL4 IL5
34 11.16 IFNG IL13 IL33 IL4 IL5
35 11.15 IFNG IL13 IL4 IL5
36 11.13 IFNG IL13
37 11.07 ICAM1 IFNG
38 10.95 CCL11 CXCL8 IL13 IL4 IL5
39 10.8 IL13 IL4 IL5
40 10.76 CCL11 IFNG IL13 IL33 IL4 IL5

GO Terms for Allergic Conjunctivitis

Cellular components related to Allergic Conjunctivitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 intracellular GO:0005622 9.63 CCL11 CXCL8 IFNG IL5 PTGDR2 TLR3
2 extracellular region GO:0005576 9.56 CCL11 CXCL8 IFNG IL13 IL33 IL4
3 extracellular space GO:0005615 9.28 CCL11 CXCL8 ICAM1 IFNG IL13 IL33

Biological processes related to Allergic Conjunctivitis according to GeneCards Suite gene sharing:

(show all 24)
# Name GO ID Score Top Affiliating Genes
1 defense response to virus GO:0051607 9.79 IFNG IL33 TLR3
2 positive regulation of angiogenesis GO:0045766 9.77 CCL11 CXCL8 TLR3
3 cellular response to tumor necrosis factor GO:0071356 9.77 CCL11 CXCL8 ICAM1
4 response to virus GO:0009615 9.74 CCL11 IFNG TLR3
5 cellular response to interferon-gamma GO:0071346 9.72 CCL11 ICAM1 TLR3
6 movement of cell or subcellular component GO:0006928 9.69 CXCL8 IFNG IL13
7 cellular response to interleukin-1 GO:0071347 9.67 CCL11 CXCL8 ICAM1
8 extrinsic apoptotic signaling pathway GO:0097191 9.63 IFNG IL33 TLR3
9 inflammatory response GO:0006954 9.63 CCL11 CXCL8 HRH1 IL13 IL5 TLR3
10 chemotaxis GO:0006935 9.62 CCL11 CXCL8 IL4 PTGDR2
11 positive regulation of interleukin-12 production GO:0032735 9.61 IFNG TLR3
12 negative regulation of osteoclast differentiation GO:0045671 9.61 IL4 TLR3
13 positive regulation of B cell proliferation GO:0030890 9.61 IL13 IL4 IL5
14 positive regulation of macrophage activation GO:0043032 9.58 IL13 IL33
15 microglial cell activation GO:0001774 9.58 IL13 TLR3
16 positive regulation of immunoglobulin secretion GO:0051024 9.56 IL33 IL5
17 positive regulation of interleukin-13 production GO:0032736 9.54 IL33 IL4
18 eosinophil chemotaxis GO:0048245 9.52 CCL11 HRH1
19 immune response GO:0006955 9.5 CCL11 CXCL8 IFNG IL13 IL4 IL5
20 type 2 immune response GO:0042092 9.48 IL33 IL4
21 negative regulation of endothelial cell apoptotic process GO:2000352 9.43 ICAM1 IL13 IL4
22 negative regulation of complement-dependent cytotoxicity GO:1903660 9.4 IL13 IL4
23 microglial cell activation involved in immune response GO:0002282 9.37 IL33 TLR3
24 regulation of receptor activity GO:0010469 9.17 CCL11 CXCL8 IFNG IL13 IL33 IL4

Molecular functions related to Allergic Conjunctivitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.17 CCL11 CXCL8 IFNG IL13 IL33 IL4
2 cytokine receptor binding GO:0005126 8.96 IL13 IL4

Sources for Allergic Conjunctivitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....